Idexx Laboratories INC /DE Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Joseph L Hooley, a Director of Idexx Laboratories Inc /De, received 49 shares of common stock on July 30, 2026.
NASDAQ
George Fennell, Executive Vice President at IDEXX Laboratories, reported transactions involving restricted stock units and common stock.
NASDAQ
IDEXX Laboratories Director Sophie V. Vandebroek was granted stock options and restricted stock units on May 12, 2026.
NASDAQ
Sam Samad, a Director at IDEXX LABORATORIES INC /DE, was granted stock options and deferred stock units on May 12, 2026.
NASDAQ
Director Karen Peacock acquired stock options and deferred stock units in IDEXX LABORATORIES INC.
NASDAQ
IDEXX Laboratories Director Lawrence D. Kingsley was granted stock options and restricted stock units on May 12, 2026, as detailed in a Form 4 filing.
NASDAQ
IDEXX Laboratories Director Daniel M. Junius was granted stock options and restricted stock units on May 12, 2026, as detailed in a Form 4 filing.
NASDAQ
IDEXX Laboratories Director Joseph L. Hooley was granted stock options and deferred stock units, with vesting tied to anniversaries or the 2027 annual meeting.
NASDAQ
Director Stuart Essig of IDEXX Laboratories acquired stock options and restricted stock units in a transaction dated May 12, 2026.
NASDAQ
Bruce L. Claflin, a Director at IDEXX LABORATORIES INC, was granted stock options and deferred stock units on May 12, 2026.
NASDAQ
Irene Chang Britt, a Director at IDEXX Laboratories, was granted stock options and deferred stock units, with vesting tied to anniversaries or the 2027 annual meeting.
NASDAQ
Director Sophie V. Vandebroek of IDEXX LABORATORIES INC /DE reported a transaction involving restricted stock units.
NASDAQ
Director M. Anne Szostak of IDEXX LABORATORIES INC reported a transaction involving 257 shares of common stock on May 7, 2026.
NASDAQ
Karen Peacock, a Director at IDEXX Laboratories Inc, acquired 101 shares of common stock on May 7, 2026, following the vesting of restricted stock units.
NASDAQ
Lawrence D. Kingsley, a Director at IDEXX LABORATORIES INC, acquired shares through the vesting of restricted stock units.
NASDAQ
IDEXX Laboratories Director Daniel M. Junius acquired 257 shares of common stock through the vesting of restricted stock units on May 7, 2026.
NASDAQ
IDEXX Laboratories Director Joseph L. Hooley acquired 158 shares of common stock through the vesting of restricted stock units on May 7, 2026.
NASDAQ
Joseph L. Hooley, a Director at IDEXX Laboratories Inc., acquired 43 deferred stock units on April 30, 2026, under the company's Director Deferred Compensation Plan.
NASDAQ
Sharon E. Underberg, EVP, GC & Corporate Secretary of IDEXX Laboratories, exercised options to acquire 197 shares of common stock.
NASDAQ
IDEXX Laboratories Executive Vice President Nimrata Hunt sold 1,758 shares of common stock for approximately $1.1 million in a pre-scheduled transaction.
NASDAQ
An amended SEC Form 4/A clarifies the equity awards granted to IDEXX Laboratories Executive Vice President Michael G. Erickson, correcting an administrative error.
NASDAQ
IDEXX Laboratories CEO Jonathan Jay Mazelsky exercised stock options and subsequently sold a significant number of common shares.
NASDAQ
IDEXX Laboratories Executive Vice President Nimrata Hunt sold 2,693 shares of common stock for approximately $1.78 million under a pre-arranged 10b5-1 trading plan.
NASDAQ
IDEXX Laboratories Executive Vice President Michael G. Erickson exercised stock options and sold a portion of the acquired shares, increasing his overall beneficial ownership.
NASDAQ
IDEXX Director Sophie V. Vandebroek exercised stock options and subsequently sold a portion of her common stock holdings.
NASDAQ
IDEXX Executive Vice President George Fennell exercised stock options and subsequently sold a portion of the acquired shares, increasing his direct beneficial ownership.
NASDAQ
IDEXX Laboratories Director Joseph L. Hooley acquired 36 deferred stock units under a compensation plan, increasing his direct beneficial ownership to 75 units.
NASDAQ
IDEXX Laboratories Director Karen Peacock received an equity grant of 101 restricted stock units and 231 non-qualified stock options as pro rata compensation for her board service.
NASDAQ
IDEXX Laboratories Executive Vice President Nimrata Hunt exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 plan.
NASDAQ
IDEXX Director Joseph L. Hooley acquired 39 deferred stock units valued at $628.54 each through the company's deferred compensation plan.